Companies › Green Valley (Shanghai) Pharmaceuticals
1 active drug program in 3 registered trials: 3 Phase 4; Neurology; next expected readout Jun 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sodium Oligomannate Capsules (GV-971) Modulator of gut microbiota and neuroinflammation | GLP1R, FFAR2 | Phase 4 | Alzheimer Disease; Alzheimer's Disease | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05058040 | Sodium Oligomannate Capsules (GV-971) | Phase 4 | Alzheimer Disease | Neurology | Jan 2025 |
| NCT05181475 | Sodium Oligomannate Capsules (GV-971) | Phase 4 | Alzheimer Disease | Neurology | Jan 2025 |
| NCT05908695 | Sodium Oligomannate Capsules (GV-971) | Phase 4 | Alzheimer's Disease | Neurology | Jun 2029 |
Prilenia Ambros Therapeutics Cerevance CereMark Pharma MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.